Volume 11, Issue 1, Pages (January 2010)

Slides:

Advertisements

Similar presentations

Fever of unknown origin and cancer: a population-based study

Advertisements

Volume 14, Issue 12, Pages (November 2013)

Volume 14, Issue 4, Pages (April 2013)

Volume 16, Issue 8, Pages (August 2015)

Volume 357, Issue 9273, Pages (June 2001)

Volume 16, Issue 2, Pages (February 2015)

Volume 367, Issue 9517, Pages (April 2006)

Volume 357, Issue 9257, Pages (March 2001)

Volume 359, Issue 9322, Pages (June 2002)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 15, Issue 1, Pages (January 2014)

Volume 16, Issue 9, Pages (September 2015)

Volume 15, Issue 6, Pages (May 2014)

Volume 376, Issue 9734, Pages (July 2010)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 373, Issue 9666, Pages (March 2009)

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 366, Issue 9482, Pages (July 2005)

Volume 13, Issue 3, Pages (March 2012)

Volume 14, Issue 3, Pages (March 2013)

Volume 12, Issue 8, Pages (August 2011)

Volume 15, Issue 4, Pages (April 2014)

Aspirin in the prevention of cancer – Author's reply

Volume 9, Issue 9, Pages (September 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 15, Issue 4, Pages (April 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 373, Issue 9663, Pages (February 2009)

Volume 14, Issue 7, Pages (June 2013)

Adjuvant chemotherapy for rectal cancer – Authors' reply

Volume 9, Issue 10, Pages (October 2008)

Volume 12, Issue 7, Pages (July 2011)

Volume 375, Issue 9732, Pages (June 2010)

Volume 18, Issue 3, Pages (March 2017)

Volume 15, Issue 1, Pages (January 2014)

Psychological response and survival in breast cancer

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma.

Volume 6, Issue 6, Pages (June 2005)

Volume 371, Issue 9624, Pages (May 2008)

Volume 13, Issue 1, Pages (January 2012)

Volume 11, Issue 4, Pages (April 2010)

Volume 9, Issue 9, Pages (September 2008)

Volume 14, Issue 11, Pages (October 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 385, Issue 9962, Pages (January 2015)

Volume 15, Issue 8, Pages (July 2014)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 18, Issue 8, Pages (August 2017)

Volume 9, Issue 4, Pages (April 2008)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 5, Issue 4, Pages (April 2018)

Volume 373, Issue 9658, Pages (January 2009)

Volume 373, Issue 9658, Pages (January 2009)

Volume 375, Issue 9714, Pages (February 2010)

Volume 15, Issue 6, Pages (May 2014)

Volume 11, Issue 3, Pages (March 2010)

Volume 371, Issue 9618, Pages (March 2008)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Volume 376, Issue 9747, Pages (October 2010)

Volume 13, Issue 7, Pages (July 2014)

Recurrence after low-dose radioiodine ablation and recombinant human thyroid- stimulating hormone for differentiated thyroid cancer (HiLo): long-term results.

Volume 8, Issue 10, Pages (October 2009)

Volume 14, Issue 7, Pages (June 2013)

Volume 371, Issue 9617, Pages (March 2008)

Volume 371, Issue 9611, Pages (February 2008)

Presentation transcript:

Volume 11, Issue 1, Pages 66-74 (January 2010) Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial Prof Jeffrey S Tobias, FRCP, Kathryn Monson, MSc, Nirmal Gupta, FRCR, Prof Hugh MacDougall, FRCR, Prof John Glaholm, FRCR, Prof Iain Hutchison, FRCS, Latha Kadalayil, PhD, Allan Hackshaw, MSc The Lancet Oncology Volume 11, Issue 1, Pages 66-74 (January 2010) DOI: 10.1016/S1470-2045(09)70306-7 Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile EFS=event-free survival. SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy. *See table 2. Only 26 patients did not fully meet the eligibility criteria, but they were included in the analysis. The Lancet Oncology 2010 11, 66-74DOI: (10.1016/S1470-2045(09)70306-7) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 2 Overall survival according to treatment groups for patients who had no surgery (A) and those who had undergone surgery (B) before randomisation SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy. The Lancet Oncology 2010 11, 66-74DOI: (10.1016/S1470-2045(09)70306-7) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 3 Event-free survival (EFS) according to treatment groups for patients who had no surgery (A) and those who had undergone surgery (B) before randomisation SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy. The Lancet Oncology 2010 11, 66-74DOI: (10.1016/S1470-2045(09)70306-7) Copyright © 2010 Elsevier Ltd Terms and Conditions